A 2025 network meta-analysis published in Metabolism , covering 22 randomized controlled trials and over 2200 participants, confirmed that tirzepatide and semaglutide were among the least effective GLP-1 agents for preserving lean mass, the very agents showing the greatest weight loss
Most of this can be explained by the link between weight and risk described in Part 1, but mortality improvements observed in clinical trials that cannot be predicted from weight-loss alone are also allowed for
Health advantages: GLP-1 medications bring down blood sugar levels, help control blood pressure, and lower the chances of heart issues
It may be supplied as a prefilled pen or vial, and you can use it at any time of day, with or without food
The company previously received the agencys fast track designation for treating moderate-to-severe OSA in obese patients